Fibroblast growth factor 23 and its receptors

Therapeutic Apheresis and Dialysis

Volumn 9, Issue 4, 2005, Pages 308-312

  Yu, Xijie ^a   White, Kenneth E ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibroblast growth factor 23; Fibrous dysplasia; Hypophosphatemia; Rickets; Tumor induced osteomalacia

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4;

ARTICLE; AUTOSOMAL DOMINANT DISORDER; BONE DEVELOPMENT; FIBROUS DYSPLASIA; HUMAN; HYPOPHOSPHATEMIA; MINERAL METABOLISM; MISSENSE MUTATION; OSTEOMALACIA; PHENOTYPE; PHOSPHATE METABOLISM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VITAMIN D METABOLISM; VITAMIN D RESISTANT RICKETS;

EID: 29144486139     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2005.00287.x     Document Type: Article

References (36)

1. The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345-8.
2. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001;60:2079-86.
3. White KE, Jonsson KB, Carn G et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 2001;86:497-500.
4. Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-63.
5. Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002;87:4957-60.
6. The HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995;11:130-6.
7. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003;278:37419-26.
8. Kumar R. Phosphatonin-a new phosphaturetic hormone? (Lessons from tumour-induced osteomalacia and X-linked hypophosphatemia). Nephrol Dial Transplant 1997;12:11-13.
9. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500-5.
10. De Beur SM, Finnegan RB, Vassiliadis J et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 2002;17:1102-10.
11. Riminucci M, Collins MT, Fedarko NS et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003;112:683-92.
12. White KE, Cabral JM, Davis SI et al. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 2005;76:361-7.
13. Ferrari SL, Bonjour JP, Rizzoli R. FGF-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005;90:1519-24.
14. Bai XY, Miao D, Goltzman D, Karaplis AC. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 2003;278:9843-9.
15. Shimada T, Urakawa I, Yamazaki Y et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004;314:409-14.
16. Larsson T, Marsell R, Schipani E et al. Transgenic mice expressing Fibroblast Growth Factor 23 under the control of the {alpha}1 (I) collagen promoter exhibit growth retardation, osteomalacia and disturbed phosphate homeostasis. Endocrinology 2004;145:3087-94.
17. Bai X, Miao D, Li J, Goltzman D, Karaplis AC. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004;145:5269-79.
18. Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004;113:561-8.
19. Sitara D, Razzaque MS, Hesse M et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004;23:421-32.
20. Ruta M, Burgess W, Givol D et al. Receptor for acidic fibroblast growth factor is related to the tyrosine kinase encoded by the fms-like gene (FLG). Proc Natl Acad Sci USA 1989;86:8722-6.
21. Ornitz DM, Xu J, Colvin JS et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996;271:15292-7.
22. Werner S, Duan DS, de Vries C, Peters KG, Johnson DE, Williams LT. Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol 1992;12:82-8.
23. Yamashita T, Konishi M, Miyake A, Inui K, Itoh N. Fibroblast growth factor (FGF) -23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 2002;277:28265-70.
24. Bowe AE, Finnegan R, Jan de Beur SM et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001;284:977-81.
25. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2:reviews 3005.1-reviews 3005.12.
26. Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 2002;16:1446-65.
27. Deng CX, Wynshaw-Boris A, Shen MM, Daugherty C, Ornitz DM, Leder P. Murine FGFR-1 is required for early postimplantation growth and axial organization. Genes Dev 1994;8:3045-57.
28. Xu X, Weinstein M, Li C et al. Fibroblast growth factor receptor 2 (FGFR2) -mediated reciprocal regulation loop between FGF8 and FGF10 is essential for limb induction. Development 1998;125:753-65.
29. Wang Y, Spatz MK, Kannan K et al. A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Proc Natl Acad Sci USA 1999;96:4455-60.
30. Weinstein M, Xu X, Ohyama K, Deng CX. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development 1998;125:3615-23.
31. Floege J, Hudkins KL, Eitner F et al. Localization of fibroblast growth factor-2 (basic FGF) and FGF receptor-1 in adult human kidney. Kidney Int 1999;56:883-97.
32. Cancilla B, Ford-Perriss MD, Bertram JF. Expression and localization of fibroblast growth factors and fibroblast growth factor receptors in the developing rat kidney. Kidney Int 1999;56:2025-39.
33. Cancilla B, Davies A, Cauchi JA, Risbridger GP, Bertram JF. Fibroblast growth factor receptors and their ligands in the adult rat kidney. Kidney Int 2001;60:147-55.
34. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004;306:1506-7.
35. Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM. FGF23 is processed by proprotein convertases but not by PHEX. Bone 2004;35:455-62.
36. i cotransporter. Am J Physiol Renal Physiol 2000;278:F792-F798.